1.7298
price down icon1.15%   -0.0202
 
loading
Precedente Chiudi:
$1.75
Aprire:
$1.71
Volume 24 ore:
102.48K
Relative Volume:
0.09
Capitalizzazione di mercato:
$5.07M
Reddito:
-
Utile/perdita netta:
$-14.07M
Rapporto P/E:
-0.269
EPS:
-6.4313
Flusso di cassa netto:
$-12.56M
1 W Prestazione:
-8.96%
1M Prestazione:
-29.11%
6M Prestazione:
-62.56%
1 anno Prestazione:
-80.72%
Intervallo 1D:
Value
$1.6901
$1.85
Intervallo di 1 settimana:
Value
$1.6901
$1.93
Portata 52W:
Value
$1.38
$22.35

Palisade Bio Inc Stock (PALI) Company Profile

Name
Nome
Palisade Bio Inc
Name
Telefono
(858) 704-4900
Name
Indirizzo
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
Name
Dipendente
9
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
PALI's Discussions on Twitter

Confronta PALI con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
PALI
Palisade Bio Inc
1.7471 5.07M 0 -14.07M -12.56M -13.99
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
407.92 105.01B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
714.47 78.17B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
629.39 37.48B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
243.25 30.94B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
114.13 27.15B 3.30B -501.07M 1.03B -2.1146

Palisade Bio Inc Borsa (PALI) Ultime notizie

pulisher
Dec 20, 2024

Palisade Bio (NASDAQ:PALI) Trading Up 2.9% – Here’s What Happened - Defense World

Dec 20, 2024
pulisher
Dec 17, 2024

Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board - Markets Insider

Dec 17, 2024
pulisher
Dec 17, 2024

Dr. Brian Feagan Appointed to Palisade Bio Clinical Advisory Board - citybiz

Dec 17, 2024
pulisher
Dec 17, 2024

Palisade Bio Strengthens Clinical Advisory Board with Leading Gastroenterology Expert for UC Drug Development - StockTitan

Dec 17, 2024
pulisher
Dec 14, 2024

PALIPalisade Bio, Inc. Latest Stock News & Market Updates - StockTitan

Dec 14, 2024
pulisher
Dec 13, 2024

Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules - GlobeNewswire

Dec 13, 2024
pulisher
Dec 13, 2024

Palisade Bio Raises $5M in Public Offering to Advance Phase 1 Clinical Trial Pipeline - StockTitan

Dec 13, 2024
pulisher
Dec 12, 2024

What's Going On With Palisade Bio Stock On Thursday? - Benzinga

Dec 12, 2024
pulisher
Dec 12, 2024

Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules - The Manila Times

Dec 12, 2024
pulisher
Dec 12, 2024

Palisade Bio Raises $5M in Public Offering to Advance Key Clinical Trial of PALI-2108 - StockTitan

Dec 12, 2024
pulisher
Dec 12, 2024

Nasdaq Down 50 Points; US Initial Jobless Claims Rise - Benzinga

Dec 12, 2024
pulisher
Dec 12, 2024

Why DBV Technologies Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket - Benzinga

Dec 12, 2024
pulisher
Dec 03, 2024

PALI Stock Plummets to 52-Week Low at $2.13 Amid Market Struggles - Investing.com

Dec 03, 2024
pulisher
Dec 03, 2024

Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects - GlobeNewswire

Dec 03, 2024
pulisher
Dec 03, 2024

Palisade Bio Reports Promising Safety Data in Phase 1 Ulcerative Colitis Drug Trial | PALI Stock News - StockTitan

Dec 03, 2024
pulisher
Dec 02, 2024

Meta Platforms Inc (META-Q) QuotePress Release - The Globe and Mail

Dec 02, 2024
pulisher
Nov 25, 2024

Brookline Capital Management Estimates Palisade Bio FY2024 Earnings - Defense World

Nov 25, 2024
pulisher
Nov 21, 2024

Palisade Bio to Present Preclinical Results for PALI-2108 - GlobeNewswire

Nov 21, 2024
pulisher
Nov 21, 2024

Palisade Bio's PALI-2108 Shows Promise in Preclinical IBD Treatment Study | PALI Stock News - StockTitan

Nov 21, 2024
pulisher
Nov 20, 2024

Brookline Capital Initiates Coverage of Palisade Bio (PALI) with Buy Recommendation - MSN

Nov 20, 2024
pulisher
Nov 15, 2024

ARMISTICE CAPITAL, LLC Acquires Shares in Palisade Bio Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) Summit - The Manila Times

Nov 14, 2024
pulisher
Nov 13, 2024

Contrasting Palisade Bio (NASDAQ:PALI) & Anavex Life Sciences (NASDAQ:AVXL) - Defense World

Nov 13, 2024
pulisher
Nov 12, 2024

Palisade Bio Inc (PALI) Quarterly 10-Q Report - Quartzy

Nov 12, 2024
pulisher
Nov 12, 2024

Palisade Bio Reports Third Quarter 2024 Financial Results - GlobeNewswire

Nov 12, 2024
pulisher
Nov 12, 2024

Palisade Bio Advances UC Drug Trial: Key Phase 1 Milestones & Patent Wins Boost Pipeline | PALI Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 07, 2024

Palisade Bio initiates phase 1 study of new UC drug - Investing.com

Nov 07, 2024
pulisher
Nov 07, 2024

Palisade Bio initiates phase 1 study of new UC drug By Investing.com - Investing.com Australia

Nov 07, 2024
pulisher
Nov 07, 2024

Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC) - The Manila Times

Nov 07, 2024
pulisher
Nov 07, 2024

Intelligent Bio Solutions Reports Fiscal 2025 First Quarter Financial Results and Operational Highlights - The Manila Times

Nov 07, 2024
pulisher
Nov 07, 2024

Palisade Bio Announces First Subject Dosed in Phase 1 - GlobeNewswire

Nov 07, 2024
pulisher
Nov 07, 2024

Palisade Bio Launches Phase 1 Trial for Novel Ulcerative Colitis Drug PALI-2108 | PALI Stock News - StockTitan

Nov 07, 2024
pulisher
Nov 04, 2024

Palisade Bio (NASDAQ:PALI) and Allogene Therapeutics (NASDAQ:ALLO) Critical Survey - Defense World

Nov 04, 2024
pulisher
Oct 31, 2024

Palisade Bio advances novel IBD treatment PALI-2108 - Investing.com

Oct 31, 2024
pulisher
Oct 31, 2024

Palisade Bio advances novel IBD treatment PALI-2108 By Investing.com - Investing.com UK

Oct 31, 2024
pulisher
Oct 31, 2024

HYCU® Recognized as CRN 2024 Product of the Year Finalist - The Manila Times

Oct 31, 2024
pulisher
Oct 31, 2024

Palisade Bio Announces Positive Data from Two Ex Vivo - GlobeNewswire

Oct 31, 2024
pulisher
Oct 31, 2024

Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis - StockTitan

Oct 31, 2024
pulisher
Oct 30, 2024

PALI stock touches 52-week low at $3.09 amid market fluctuations - Investing.com

Oct 30, 2024
pulisher
Oct 24, 2024

Alto Neuroscience’s depression drug trial fails at phase 2 - BioPharma-Reporter.com

Oct 24, 2024
pulisher
Oct 24, 2024

Alto Neuroscience’s Depression Trial Failure Sends Shares Into Downward Spiral - MedCity News

Oct 24, 2024
pulisher
Oct 15, 2024

Palisade Bio Announces Abstract Accepted for Presentation - GlobeNewswire

Oct 15, 2024
pulisher
Oct 12, 2024

Sutro Biopharma (NASDAQ:STRO) & Palisade Bio (NASDAQ:PALI) Head-To-Head Contrast - Defense World

Oct 12, 2024
pulisher
Oct 12, 2024

Meta Platforms (NASDAQ:META) Shares Up 0.6% Following Analyst Upgrade - Defense World

Oct 12, 2024
pulisher
Oct 11, 2024

Palisade Bio receives Health Canada nod for UC drug trial By Investing.com - Investing.com Australia

Oct 11, 2024
pulisher
Oct 10, 2024

Palisade Bio receives Health Canada nod for UC drug trial - Investing.com

Oct 10, 2024
pulisher
Oct 10, 2024

Palisade Bio Cleared by Health Canada to Commence Phase 1 - GlobeNewswire

Oct 10, 2024
pulisher
Oct 10, 2024

Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC) - Yahoo Finance

Oct 10, 2024
pulisher
Oct 08, 2024

Palisade Bio to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC - The Manila Times

Oct 08, 2024
pulisher
Oct 04, 2024

Pre-market Movers: GANX, TFFP, AKYA, CLDI... - RTTNews

Oct 04, 2024
pulisher
Sep 28, 2024

Palisade Bio, Inc. (NASDAQ:PALI) Shares Sold by Armistice Capital LLC - Defense World

Sep 28, 2024

Palisade Bio Inc Azioni (PALI) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Palisade Bio Inc Azioni (PALI) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Wei Binxian
Director
Nov 21 '24
Option Exercise
0.00
388
0
855
Wei Binxian
Director
Jun 11 '24
Option Exercise
0.00
465
0
467
Williams Donald Allen
Director
Jun 11 '24
Option Exercise
0.00
340
0
340
Jones Mitchell Lawrence
Chief Medical Officer
May 28 '24
Option Exercise
0.00
4,290
0
4,313
Finley John David
CEO, CFO, Director
May 28 '24
Option Exercise
0.00
7,068
0
14,079
Williams Donald Allen
Director
May 28 '24
Buy
4.86
1,000
4,863
1,000
Finley John David
CEO, CFO, Director
May 24 '24
Buy
4.81
1,000
4,810
8,437
Jones Mitchell Lawrence
CEO, CFO, Director
May 06 '24
Option Exercise
0.00
460
0
880
Finley John David
CEO, CFO, Director
May 06 '24
Option Exercise
0.00
443
0
6,832
Finley John David
CEO, CFO, Director
Mar 11 '24
Option Exercise
0.00
5,558
0
96,849
$69.91
price up icon 0.10%
$19.00
price up icon 1.18%
$40.08
price up icon 1.72%
$362.23
price up icon 0.37%
$181.62
price up icon 2.21%
$114.13
price down icon 0.79%
Capitalizzazione:     |  Volume (24 ore):